SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?


To: jont who wrote (467)1/14/1999 9:07:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 642
 
Jont, thanks. Various analysts also recommended the drug stocks (LLY, WLA, PFE, SGP) on CNBC. To used a cliche, a great buying opportunity.

Anthony



To: jont who wrote (467)1/14/1999 9:22:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 642
 
Eli Lilly & Co Raised to 'Strong Buy' at ING Baring Furman

Bloomberg News
January 14, 1999, 10:50 a.m. PT

Princeton, New Jersey, Jan. 14 (Bloomberg Data) -- Eli Lilly & Co. (LLY
US) was raised to ''strong buy'' from ''buy'' by analyst James E. Flynn at ING
Baring Furman Selz LLC. The 12-month target price is $95.00 per share.

-- Michael O. Donohue in Princeton, New Jersey, (609)279-3156



To: jont who wrote (467)1/25/1999 9:17:00 AM
From: Anthony Wong  Respond to of 642
 
Settlement Reached in Prozac Patent Case; $4 Million Agreement Permanently Removes Two Claims From Patent Challenge
Monday January 25, 8:38 am Eastern Time
biz.yahoo.com